Casper C. Theaetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol, 2005, 129(1): 3-17. DOI: 10.1111/j.1365-2141. 2004.05311.x.
[2]
Janez L, Taban M, Wong CA, et al. Localized intraorbital Castleman's disease: A case report. Orbit, 2010, 29(3): 158-160. DOI: 10.3109/01676830903537138.
[3]
Mukherjee B, Alam MS, Krishnakumar S. A rare case of bilateral orbital Castleman disease. Orbit, 2014, 33(4): 314-317. DOI: 10.3109/01676830.2014.904381.
[4]
Jones NW, Fountain TR, Thakral B, et al. Castleman's disease in the orbit of a 17-year-old girl: A case report. Ophthalmic Plast Reconstr Surg, 2014, 301(1): e17-20. DOI: 10.1097/ IOP.0b013e31828b0e18.
[5]
Venizelos I, Papathomas TG, Papathanasiou M, et al. Orbital involvement in Castleman disease. Surv Ophthalmol, 2010, 55(3): 247-255. DOI: 10.1016/j.survophthal.2009.09.003.
Park K, Choi Y, Song K. Hyaline-vascular type Castleman's disease involving both orbits. Acta ophthalmol Scand, 2002, 80(5): 537-539. DOI: 10.1034/j.1600-0420.2002.800514.x.
[9]
Menke D, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol, 2002, 117(2): 268-275. DOI: 10.1309/7243-AV50-KJ28-V6J9.
[10]
Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: Proposed pathomechanism of vascular proliferation in the affected lymph node. Leu lymphoma, 2000, 38(3-4): 387-394. DOI: 10.3109/10428190009087030.
浙公网安备 33030202001892号